$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-K Financial Statement

#000114420417015137 Filed on March 16, 2017

Income Statement

Concept	2017 Q1	2016 Q4	2016
Revenue	$2.778M	$14.41M	$16.48M
YoY Change	320.91%	4161.83%	1809.62%
Cost Of Revenue	$469.0K	$430.0K	$790.0K
YoY Change
Gross Profit	$2.309M	$12.19M	$15.69M
YoY Change			1718.08%
Gross Profit Margin	83.12%	84.62%	95.21%
Selling, General & Admin	$10.25M	$8.590M	$34.00M
YoY Change	29.28%	19.14%	57.54%
% of Gross Profit	444.0%	70.47%	216.72%
Research & Development	$8.404M	$10.58M	$35.13M
YoY Change	8.63%	83.68%	17.86%
% of Gross Profit	363.97%	86.79%	223.93%
Depreciation & Amortization	$682.0K	$830.0K	$944.0K
YoY Change	16950.0%	8200.0%	3530.77%
% of Gross Profit	29.54%	6.81%	6.02%
Operating Expenses	$62.26M	$31.42M	$82.19M
YoY Change	295.27%	142.44%	59.92%
Operating Profit	-$19.13M	-$32.22M	-$65.71M
YoY Change	22.82%	148.51%	30.04%
Interest Expense	$698.0K	-$2.000M	$3.690M
YoY Change	12.58%	-18.37%	148.65%
% of Operating Profit
Other Income/Expense, Net	$3.015M		-$5.580M
YoY Change	-294.27%		66.47%
Pretax Income	-$14.56M	-$21.30M	-$71.29M
YoY Change	-12.5%	41.25%	32.31%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$11.98M	-$17.43M	-$55.10M
YoY Change	-1.83%	44.82%	13.77%
Net Earnings / Revenue	-431.32%	-121.01%	-334.31%
Basic Earnings Per Share
Diluted Earnings Per Share	-$296.8K	-$433.7K	-$1.379M
COMMON SHARES
Basic Shares Outstanding	50.32M shares	48.88M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q4	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$135.2M	$90.70M	$90.70M
YoY Change	66.09%	-7.64%	-7.64%
Cash & Equivalents	$150.9M	$105.2M	$88.30M
Short-Term Investments	$1.200M	$2.400M	$2.400M
Other Short-Term Assets	$9.500M	$10.10M	$10.10M
YoY Change	493.75%	531.25%	531.25%
Inventory	$204.0K	$203.0K	$200.0K
Prepaid Expenses
Receivables	$1.400M	$1.830M	$1.800M
Other Receivables	$5.400M	$6.900M	$6.900M
Total Short-Term Assets	$151.8M	$109.6M	$109.6M
YoY Change	80.07%	9.7%	9.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.400M	$7.376M	$7.400M
YoY Change	184.62%	2287.06%	2366.67%
Goodwill	$18.65M	$18.65M
YoY Change
Intangibles
YoY Change
Long-Term Investments	$300.0K	$300.0K	$1.400M
YoY Change	20.0%	20.0%	-44.0%
Other Assets	$16.30M	$394.0K	$16.30M
YoY Change	8.67%	816.28%	11.64%
Total Long-Term Assets	$60.10M	$61.10M	$61.10M
YoY Change	191.75%	227.19%	226.74%
TOTAL ASSETS
Total Short-Term Assets	$151.8M	$109.6M	$109.6M
Total Long-Term Assets	$60.10M	$61.10M	$61.10M
Total Assets	$211.9M	$170.7M	$170.7M
YoY Change	102.0%	43.94%	43.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.90M	$24.30M	$24.30M
YoY Change	982.61%	1200.86%	1178.95%
Accrued Expenses	$11.12M	$10.08M	$12.00M
YoY Change	42.56%	17.64%	48.15%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.300M	$2.000M	$2.000M
YoY Change
Total Short-Term Liabilities	$52.80M	$56.57M	$56.60M
YoY Change	388.89%	434.69%	433.96%
LONG-TERM LIABILITIES
Long-Term Debt	$27.80M	$26.20M	$26.20M
YoY Change	33.65%	12.93%	12.93%
Other Long-Term Liabilities	$5.000M	$5.014M	$5.000M
YoY Change	108.33%	758.56%	733.33%
Total Long-Term Liabilities	$32.80M	$5.014M	$31.20M
YoY Change	41.38%	758.56%	31.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$52.80M	$56.57M	$56.60M
Total Long-Term Liabilities	$32.80M	$5.014M	$31.20M
Total Liabilities	$164.2M	$87.76M	$132.2M
YoY Change	172.31%	155.59%	113.92%
SHAREHOLDERS EQUITY
Retained Earnings		-$245.3M
YoY Change		28.97%
Common Stock		$49.00K
YoY Change		4.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$47.70M	$38.50M	$38.50M
YoY Change
Total Liabilities & Shareholders Equity	$211.9M	$170.7M	$170.7M
YoY Change	102.0%	43.94%	43.93%

Cashflow Statement

Concept	2017 Q1	2016 Q4	2016
OPERATING ACTIVITIES
Net Income	-$11.98M	-$17.43M	-$55.10M
YoY Change	-1.83%	44.82%	13.77%
Depreciation, Depletion And Amortization	$682.0K	$830.0K	$944.0K
YoY Change	16950.0%	8200.0%	3530.77%
Cash From Operating Activities	-$11.48M	-$17.97M	-$45.81M
YoY Change	-1.42%	-728.32%	124.81%
INVESTING ACTIVITIES
Capital Expenditures	$261.0K	-$610.0K	$6.370M
YoY Change	-88.62%	221.05%	2150.88%
Acquisitions	$4.626M		$4.626M
YoY Change
Other Investing Activities	-$680.0K	-$690.0K	$660.0K
YoY Change	223.81%	-102.34%	-92.99%
Cash From Investing Activities	-$942.0K	-$1.300M	-$6.060M
YoY Change	-65.11%	-104.44%	-176.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$58.16M	25.96M	$42.91M
YoY Change	-2493.42%	-35.84%	-29.57%
NET CHANGE
Cash From Operating Activities	-$11.48M	-17.97M	-$45.81M
Cash From Investing Activities	-$942.0K	-1.300M	-$6.060M
Cash From Financing Activities	$58.16M	25.96M	$42.91M
Net Change In Cash	$45.74M	6.690M	-$8.967M
YoY Change	-372.77%	-90.79%	-118.52%
FREE CASH FLOW
Cash From Operating Activities	-$11.48M	-$17.97M	-$45.81M
Capital Expenditures	$261.0K	-$610.0K	$6.370M
Free Cash Flow	-$11.74M	-$17.36M	-$52.18M
YoY Change	-15.77%	-669.18%	152.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	98182000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	88000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10579000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	14586000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	16480000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	863000	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	82190000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	51394000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	20652000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-65710000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	298000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	245000	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	662000	USD
CY2016	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-1071000	USD
CY2015	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	-1675000	USD
CY2014	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	942000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5580000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3352000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	266000	USD
CY2016	us-gaap	Profit Loss ProfitLoss	-71290000	USD
CY2015	us-gaap	Profit Loss ProfitLoss	-53883000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9061000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1599000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	109634000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	99937000	USD
CY2016Q4	us-gaap	Assets Assets	170731000	USD
CY2015Q4	us-gaap	Assets Assets	118610000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88294000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7376000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	309000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	394000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	43000	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	27000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	56565000	USD
CY2016Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	22528000	USD
CY2015Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	23174000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5014000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	584000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	87763000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	34337000	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	47000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	283697000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	246955000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-245251000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190156000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	38495000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	56846000	USD
CY2016Q4	us-gaap	Minority Interest MinorityInterest	44473000	USD
CY2015Q4	us-gaap	Minority Interest MinorityInterest	27427000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-50531000	USD
CY2016Q4	us-gaap	Long Term Investments LongTermInvestments	1414000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-20652000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-20386000	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39962657	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39146589	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	36323596	shares
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	118610000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5395000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	5889000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	82968000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	84273000	USD
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1250000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	17408000	USD
CY2015Q4	us-gaap	Long Term Investments LongTermInvestments	2485000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	15860000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	481000	USD
CY2015Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	114000	USD
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.24
CY2014	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	0	USD
CY2014	us-gaap	Profit Loss ProfitLoss	-20386000	USD
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-16195000	USD
CY2015	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-5455000	USD
CY2014	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-55095000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-48428000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2016	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2015	us-gaap	Other Noncash Expense OtherNoncashExpense	167000	USD
CY2014	us-gaap	Other Noncash Expense OtherNoncashExpense	634000	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1466000	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	314000	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	12128000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	14291000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	5546000	USD
CY2016	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	0	USD
CY2015	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	0	USD
CY2014	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-398000	USD
CY2016	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	4346000	USD
CY2015	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	195000	USD
CY2014	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-464000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-45813000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-20378000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16334000	USD
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
CY2014	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	346000	USD
CY2016	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
CY2015	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	0	USD
CY2014	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	2925000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6370000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	283000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	350000	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1250000	USD
CY2014	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2016	fbio	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	-53000	USD
CY2015	fbio	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	-958000	USD
CY2014	fbio	Issuance Of Common Stock For License Expenses IssuanceOfCommonStockForLicenseExpenses	0	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	79947000	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	20002000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	99949000	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2016	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	0	USD
CY2015	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	22000	USD
CY2014	us-gaap	Proceeds From Mortgage Deposits ProceedsFromMortgageDeposits	0	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6060000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	7885000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-23273000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	204000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	739000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	124000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-849000	USD
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	61000	USD
CY2015	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1000	USD
CY2014	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-81000	USD
CY2016	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2015	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2014	us-gaap	Asset Impairment Charges AssetImpairmentCharges	722000	USD
CY2015	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	10448000	USD
CY2014	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	USD
CY2016	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	3785000	USD
CY2015	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	10448000	USD
CY2014	fbio	Payment For Research And Development Licenses PaymentForResearchAndDevelopmentLicenses	0	USD
CY2016	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	3785000	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	13654000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3502000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	216000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	596000	USD
CY2016	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	189000	USD
CY2015	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	59000	USD
CY2014	fbio	Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan	19000	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	39662000	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	57817000	USD
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2016	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	2844000	USD
CY2015	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	6321000	USD
CY2014	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	USD
CY2014	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	14009000	USD
CY2016	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
CY2015	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	10000000	USD
CY2014	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49759000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99521000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-9888000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	48423000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-49762000	USD
CY2016	us-gaap	Interest Paid InterestPaid	349000	USD
CY2015	us-gaap	Interest Paid InterestPaid	80000	USD
CY2014	us-gaap	Interest Paid InterestPaid	785000	USD
CY2016	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2000	USD
CY2015	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1000	USD
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	41985000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	60916000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-10155000	USD
CY2014	us-gaap	Gain Loss On Sales Of Assets And Asset Impairment Charges GainLossOnSalesOfAssetsAndAssetImpairmentCharges	400000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	15900000	USD
CY2016	fbio	Percentage Of Tax Benefit Likely Of Being Realized PercentageOfTaxBenefitLikelyOfBeingRealized	0.5	pure
CY2016	us-gaap	Depreciation Depreciation	400000	USD
CY2015Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	599	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12239	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94688	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	7790	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.05	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.06	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.04	pure
CY2015	us-gaap	Depreciation Depreciation	26000	USD
CY2014	us-gaap	Depreciation Depreciation	23000	USD
CY2014Q1	us-gaap	Equity Method Investments EquityMethodInvestments	250000	USD
CY2014Q1	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.35	pure
CY2016Q4	us-gaap	Equity Method Investments EquityMethodInvestments	300000	USD
CY2015Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	4442	USD
CY2016Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	742	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	10899	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	8158	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	4025	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	210	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6305	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4583	USD
CY2016Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	1095	USD
CY2015Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	358	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	106927	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	72599	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	66730	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5869	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	76486	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	54249	USD
CY2016Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	7277	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.01	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.44	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.45	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.33	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.03	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.03	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0	pure
CY2015	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	24000	USD
CY2014	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	100000	USD
CY2008Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04	pure
CY2016Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	53000	USD
CY2015Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	0	USD
CY2016Q4	fbio	Lease Impairment Current LeaseImpairmentCurrent	128000	USD
CY2015Q4	fbio	Lease Impairment Current LeaseImpairmentCurrent	146000	USD
CY2016Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2634000	USD
CY2014Q4	us-gaap	Capital Leases Future Minimum Payments Receivable Current CapitalLeasesFutureMinimumPaymentsReceivableCurrent	500000	USD
CY2015	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	200000	USD
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0.1	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	83000	USD
CY2014Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2700000	USD
CY2015Q4	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	6100	sqft
CY2015Q4	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2015Q4	fbio	Lease Expiration Period LeaseExpirationPeriod	P5Y
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	0.4	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	0.3	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	7700000	shares
CY2016	fbio	Share Based Compensation Arrangement By Share Based Payment Award Contractual Term Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualTermOfAward	P10Y
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	9978201	shares
CY2015	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	14291000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	9900000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	6900000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	4000000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	11600000	USD
CY2016Q4	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2016	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	0.1	USD
CY2015	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	45000	USD
CY2014	fbio	Employee Stock Purchase Plan Compensation Expense Recognized EmployeeStockPurchasePlanCompensationExpenseRecognized	25000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1500000	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13676979	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9889452	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9058166	shares
CY2016	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	60668000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2846000	USD
CY2015Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2492000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1253000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	382000	USD
CY2016Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	394000	USD
CY2015Q4	fbio	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	303000	USD
CY2016Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	900000	USD
CY2015Q4	fbio	Other Short Term Liabilities Related To Manufacturing Rights OtherShortTermLiabilitiesRelatedToManufacturingRights	2007000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1148000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	523000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10082000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8570000	USD
CY2016Q4	us-gaap	Other Liabilities OtherLiabilities	2500000	EUR
CY2014	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	200000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	30224000	USD
CY2015Q4	us-gaap	Long Term Debt LongTermDebt	24009000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	2009000	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	835000	USD
CY2016	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	5532000	USD
CY2015	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	11408000	USD
CY2014	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2016	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	200000	USD
	fbio	Value Of Warrants Issued ValueOfWarrantsIssued	200000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2016Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3975000	USD
CY2016Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3871000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-12478000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-12981000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-17431000	USD
CY2015Q4	fbio	Value Of Warrants Issued ValueOfWarrantsIssued	600000	USD
CY2015Q4	fbio	Warrants Issued WarrantsIssued	139592	shares
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	0	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	25000	USD
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	338000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12571000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7762000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18097000	USD
CY2015Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-12964000	USD
CY2015Q1	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-464000	USD
CY2015Q2	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	1344000	USD
CY2015Q3	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-1783000	USD
CY2015Q4	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-2449000	USD
CY2015Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	479000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	243000	USD
CY2015Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1694000	USD
CY2015Q4	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3039000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-6175000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-18161000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-12036000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	500000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-12056000	USD
CY2016Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2230000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	975000	USD
CY2016Q4	us-gaap	Sales Revenue Net SalesRevenueNet	14405000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15571000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17042000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17180000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-32217000	USD
CY2016Q1	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-1552000	USD
CY2016Q2	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-1253000	USD
CY2016Q3	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-710000	USD
CY2016Q4	fbio	Nonoperating Income Expense Including Interest Income Expense Net NonoperatingIncomeExpenseIncludingInterestIncomeExpenseNet	-2065000	USD
CY2016Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	4438000	USD
CY2016Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	3911000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2016Q1	us-gaap	Sales Revenue Net SalesRevenueNet	660000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-12205000	USD
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q2	dei	Entity Public Float EntityPublicFloat	78431868	USD
CY2016	dei	Trading Symbol TradingSymbol	FBIO
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	50319919	shares
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1830000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2016Q4	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	1030000	USD
CY2015Q4	us-gaap	Deposits With Clearing Organizations And Others Securities DepositsWithClearingOrganizationsAndOthersSecurities	0	USD
CY2016Q4	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	3357000	USD
CY2015Q4	us-gaap	Receivables From Brokers Dealers And Clearing Organizations ReceivablesFromBrokersDealersAndClearingOrganizations	0	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1712000	USD
CY2015Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0	USD
CY2016Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	2357000	USD
CY2015Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	0	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	203000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2016Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	1790000	USD
CY2015Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	156000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	18645000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	0	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24295000	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	10438000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11940000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	0	USD
CY2016Q4	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	995000	USD
CY2015Q4	us-gaap	Deferred Revenue And Credits Current DeferredRevenueAndCreditsCurrent	0	USD
CY2016Q4	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue	298000	USD
CY2015Q4	us-gaap	Financial Instruments Sold Not Yet Purchased At Fair Value FinancialInstrumentsSoldNotYetPurchasedAtFairValue	0	USD
CY2016Q4	fbio	Warrants Issuable Current WarrantsIssuableCurrent	14359000	USD
CY2015Q4	fbio	Warrants Issuable Current WarrantsIssuableCurrent	0	USD
CY2016Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	77000	USD
CY2015Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2016Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1000000	USD
CY2015Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	USD
CY2016Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1031000	USD
CY2015Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2016Q4	fbio	Contingently Issuable Liabilities Current ContingentlyIssuableLiabilitiesCurrent	1682000	USD
CY2015Q4	fbio	Contingently Issuable Liabilities Current ContingentlyIssuableLiabilitiesCurrent	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	5869	USD
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><b><font style="FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 29.7pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"><font style="FONT-SIZE: 10pt">The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. </font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	319000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	USD
CY2016Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	3656000	USD
CY2015Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	0	USD
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48932023	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47147032	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48932023	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47147032	shares
CY2016Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.39	pure
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	22872000	USD
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4626000	USD
CY2016	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	190556000	USD
CY2016	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	3690000	USD
CY2015	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	1484000	USD
CY2014	fbio	Interestexpenseandfinancefees Interestexpenseandfinancefees	1338000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1039000	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	438000	USD
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2016	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	-78000	USD
CY2015	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	0	USD
CY2014	fbio	Changeinfairvalueofsubsidiaryconvertiblenote Changeinfairvalueofsubsidiaryconvertiblenote	0	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	27498000	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	4889000	USD
CY2016Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash Deposites With Clearing Organizations BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashDepositesWithClearingOrganizations	1030000	USD
CY2016Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Receivable From Brokers Dealers And Clearing Agencies BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReceivableFromBrokersDealersAndClearingAgencies	1607000	USD
CY2016Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Securities Owned Fair Value BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedSecuritiesOwnedFairValue	2178000	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	1985000	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	1132000	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther	353000	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	75817000	USD
CY2016Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Compensation Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationPayable	14029000	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	6079000	USD
CY2016Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Clearing And Marketing Credits BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredClearingAndMarketingCredits	1007000	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	707000	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities	35228000	USD
CY2016Q4	us-gaap	Business Combination Acquisition Of Less Than100 Percent Noncontrolling Interest Fair Value BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue	17717000	USD
CY2016Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Less Noncontrolling Interest BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest	22872000	USD
CY2016	fbio	Cash And Cash Equivalents Acquired From Business Combination CashAndCashEquivalentsAcquiredFromBusinessCombination	27498000	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	163909000	USD
CY2016	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-59027000	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-47310000	USD
CY2016	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.48
CY2015	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-1.21
CY2016	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.48
CY2015	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.21
CY2016	us-gaap	Interest Expense InterestExpense	3690000	USD
CY2015	us-gaap	Interest Expense InterestExpense	1484000	USD
CY2014	us-gaap	Interest Expense InterestExpense	1338000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	596000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	216000	USD
CY2016	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	1032000	USD
CY2015	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
CY2016	fbio	Percentage Of Cash Flow Pursuant To Asc470 PercentageOfCashFlowPursuantToAsc470	0.1	pure
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1200000	USD
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	36000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1164000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	400000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	81278000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70523000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	944000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	23000	USD
CY2016	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	183000	USD
CY2015	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	0	USD
CY2014	us-gaap	Cost Of Goods Sold Amortization CostOfGoodsSoldAmortization	0	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	14291000	USD
CY2014	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	3502000	USD
CY2014	fbio	Adjustments To Additional Paid In Capital Stock Issued At Market Offering Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedAtMarketOfferingIssuanceCosts	32000	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2014	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
CY2015	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	51496000	USD
CY2016	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	36818000	USD
CY2014	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	19000	USD
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	59000	USD
CY2015	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	958000	USD
CY2016	fbio	Adjustments To Additional Paid In Capital Stock Issued For License Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses	53000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	5546000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	613000	USD
CY2015	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	12128000	USD
CY2016	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	0	USD
CY2016	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	434000	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	189000	USD
CY2016	fbio	Adjustments To Additional Paid In Capital At Market Offering Costs AdjustmentsToAdditionalPaidInCapitalAtMarketOfferingCosts	-79000	USD
CY2016	fbio	Stock Cancelled During Period Value Restricted Stock Award StockCancelledDuringPeriodValueRestrictedStockAward	0	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	2006000	USD
CY2016	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	0	USD
CY2016	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	17643000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1830000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	203000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2016	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	1634000	USD
CY2015	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	156000	USD
CY2014	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	15000	USD
CY2016	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	175000	USD
CY2015	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	158000	USD
CY2014	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	USD
CY2016	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	176000	USD
CY2015	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	0	USD
CY2014	fbio	Amortization Of Forgivable Loans To Registered Representatives AmortizationOfForgivableLoansToRegisteredRepresentatives	0	USD
CY2016	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	-13000	USD
CY2015	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	0	USD
CY2014	fbio	Amortization Of Deferred Clearing Credit AmortizationOfDeferredClearingCredit	0	USD
CY2016	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	47000	USD
CY2015	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2014	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	0	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-73000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2016	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	1039000	USD
CY2015	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	438000	USD
CY2014	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	0	USD
CY2016	fbio	Change In Fair Value Of Contingent Consideration Payable ChangeInFairValueOfContingentConsiderationPayable	2000	USD
CY2015	fbio	Change In Fair Value Of Contingent Consideration Payable ChangeInFairValueOfContingentConsiderationPayable	0	USD
CY2014	fbio	Change In Fair Value Of Contingent Consideration Payable ChangeInFairValueOfContingentConsiderationPayable	0	USD
CY2015Q4	fbio	Accrued Expenses Releted To Dr Falk Pharma Milestone AccruedExpensesReletedToDrFalkPharmaMilestone	2717000	USD
CY2016	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	4048000	USD
CY2015	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	0	USD
CY2014	us-gaap	Increase Decrease In Broker Dealer Related Receivables Payables Net IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet	0	USD
CY2016	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	84000	USD
CY2015	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	0	USD
CY2014	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	0	USD
CY2016	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	179000	USD
CY2015	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	0	USD
CY2014	us-gaap	Increase Decrease In Marketable Securities Restricted IncreaseDecreaseInMarketableSecuritiesRestricted	0	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2016	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	12000	USD
CY2015	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2014	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2016	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	298000	USD
CY2015	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	0	USD
CY2014	us-gaap	Increase Decrease In Financial Instruments Sold Not Yet Purchased IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased	0	USD
CY2016	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	66000	USD
CY2015	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	0	USD
CY2014	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	0	USD
CY2016	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	6000	USD
CY2015	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	0	USD
CY2014	us-gaap	Payments For Mortgage Deposits PaymentsForMortgageDeposits	0	USD
CY2016	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	4626000	USD
CY2015	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	USD
CY2014	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	USD
CY2016	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	434000	USD
CY2015	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	0	USD
CY2014	fbio	Proceeds From Issuance Of At Market Offering ProceedsFromIssuanceOfAtMarketOffering	0	USD
CY2015	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2016	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2015	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	855000	USD
CY2014	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2016	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	7000000	USD
CY2015	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	0	USD
CY2014	us-gaap	Proceeds From Unsecured Lines Of Credit ProceedsFromUnsecuredLinesOfCredit	0	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2014	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	32000	USD
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2016	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	79000	USD
CY2015	fbio	Payment Of Cost Related To Atthemarket Offering PaymentOfCostRelatedToAtthemarketOffering	0	USD
CY2016	fbio	Payment Of Nsc Note PaymentOfNscNote	6392000	USD
CY2015	fbio	Payment Of Nsc Note PaymentOfNscNote	0	USD
CY2014	fbio	Payment Of Nsc Note PaymentOfNscNote	0	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	634000	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	114000	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2016	fbio	Non Cash Or Part Non Cash Acquisition Beneficial Conversion Feature Related To Opus Credit Facility NonCashOrPartNonCashAcquisitionBeneficialConversionFeatureRelatedToOpusCreditFacility	2006000	USD
CY2015	fbio	Non Cash Or Part Non Cash Acquisition Beneficial Conversion Feature Related To Opus Credit Facility NonCashOrPartNonCashAcquisitionBeneficialConversionFeatureRelatedToOpusCreditFacility	0	USD
CY2014	fbio	Non Cash Or Part Non Cash Acquisition Beneficial Conversion Feature Related To Opus Credit Facility NonCashOrPartNonCashAcquisitionBeneficialConversionFeatureRelatedToOpusCreditFacility	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Goodwill NoncashOrPartNoncashAcquisitionGoodwill	-18645000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Goodwill NoncashOrPartNoncashAcquisitionGoodwill	0	USD
CY2014	fbio	Noncash Or Part Noncash Acquisition Goodwill NoncashOrPartNoncashAcquisitionGoodwill	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	-4889000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1 NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Cash Deposits With Claening Organisations NoncashOrPartNoncashAcquisitionCashDepositsWithClaeningOrganisations	-1030000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Cash Deposits With Claening Organisations NoncashOrPartNoncashAcquisitionCashDepositsWithClaeningOrganisations	0	USD
CY2014	fbio	Noncash Or Part Noncash Acquisition Cash Deposits With Claening Organisations NoncashOrPartNoncashAcquisitionCashDepositsWithClaeningOrganisations	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations	-1607000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations	0	USD
CY2014	fbio	Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	-2178000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Investments Acquired1 NoncashOrPartNoncashAcquisitionInvestmentsAcquired1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	-1985000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	-1132000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Restricted Cash NoncashOrPartNoncashAcquisitionRestrictedCash	-353000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Restricted Cash NoncashOrPartNoncashAcquisitionRestrictedCash	0	USD
CY2014	fbio	Noncash Or Part Noncash Acquisition Restricted Cash NoncashOrPartNoncashAcquisitionRestrictedCash	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	-6079000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1 NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1	-14029000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1 NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1 NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1	0	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed	-1007000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed	0	USD
CY2014	fbio	Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1	-707000	USD
CY2016	fbio	Noncash Or Part Noncash Acquisition Noncontrolling Interests NoncashOrPartNoncashAcquisitionNoncontrollingInterests	17717000	USD
CY2015	fbio	Noncash Or Part Noncash Acquisition Noncontrolling Interests NoncashOrPartNoncashAcquisitionNoncontrollingInterests	0	USD
CY2014	fbio	Noncash Or Part Noncash Acquisition Noncontrolling Interests NoncashOrPartNoncashAcquisitionNoncontrollingInterests	0	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	4626000	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	USD
CY2016Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	1414000	USD
CY2016Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	1414000	USD
CY2016Q4	us-gaap	Liabilities Fair Value Disclosure Recurring LiabilitiesFairValueDisclosureRecurring	5168000	USD
CY2015Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	2599000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	19089000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1071000	USD
CY2016	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	78000	USD
CY2016	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	1039000	USD
CY2016	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	793000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	20942000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	4160000	USD
CY2015	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	289000	USD
CY2015	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	-1675000	USD
CY2015	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings	438000	USD
CY2015	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	613000	USD
CY2016Q4	fbio	Equity Securities Called By Warrant EquitySecuritiesCalledByWarrant	10000	USD
CY2016	us-gaap	Investments In And Advances To Affiliates At Fair Value Period Increase Decrease InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease	1100000	USD
CY2014Q2	us-gaap	Short Term Investments ShortTermInvestments	243000	USD
CY2016	us-gaap	Revenues Revenues	16480000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	-790000	USD
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5774000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	-35134000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	-28229000	USD
CY2015	us-gaap	Revenues Revenues	863000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	0	USD
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2850000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	-29810000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	-18734000	USD
CY2016Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	5014000	USD
CY2015Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	584000	USD
CY2016Q4	fbio	Jmc Accrued Cost Of Goods Sold JmcAccruedCostOfGoodsSold	726000	USD
CY2015Q4	fbio	Jmc Accrued Cost Of Goods Sold JmcAccruedCostOfGoodsSold	0	USD
CY2012Q4	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	8700	sqft
CY2012	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	0.1	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	0.6	USD
CY2016Q4	us-gaap	Other Liabilities OtherLiabilities	2600000	USD
CY2015	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	32882000	USD
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Mustang or any of its respective subsidiaries that occurs after the effective date of the Mustang Founders Agreement and ending on the date when the Company no longer has majority voting control in Mustang’s voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Mustang’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, Mustang will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	50000	shares
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4100000	USD
CY2016	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2016Q2	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	33958	shares
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	2.40
CY2016Q2	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2016Q2	us-gaap	Share Price SharePrice	2.82
CY2016Q4	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	52769	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	2.03
CY2016Q4	fbio	Employee Stock Purchase Plan Offering Fair Value Reckoning Percentage EmployeeStockPurchasePlanOfferingFairValueReckoningPercentage	0.85	pure
CY2016Q4	us-gaap	Share Price SharePrice	2.39
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	1950000	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	366666	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	1250000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	333334	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	7.00	shares
CY2016	fbio	Warrant Purchase Price Per Unit WarrantPurchasePricePerUnit	50000	USD
CY2016	fbio	Percentage Of Placement Agent Fee PercentageOfPlacementAgentFee	0.10	pure
CY2016	fbio	Net Proceeds From Issuance Of Warrants NetProceedsFromIssuanceOfWarrants	51500000	USD
CY2016	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-920000	USD
CY2015	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	0	USD
CY2014	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-14586000	USD
CY2016Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	98	USD
CY2015Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	4449	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	2806000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2692000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2713000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	2754000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	2622000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	27261000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	40848000	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2014	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9000	USD
CY2016Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	71800	USD
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to the Company, on the anniversary date of the Checkpoint Founders Agreement, shares of common stock equal to 2.5% of the fully-diluted outstanding equity of Checkpoint at the time of issuance; (ii) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Checkpoint or any of its subsidiaries that occurs after the effective date of the Checkpoint Founders Agreement and ending on the date when the Company no longer has majority voting control in Checkpoint’s voting equity, equal to 2.5% of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to 4.5% of Checkpoint’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Checkpoint Founders Agreement), Checkpoint will pay a one-time change in control fee equal to five times (5x) the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) pay an equity fee in shares of Helocyte common stock, payable within five (5) business days of the closing of any equity or debt financing for Helocyte or any of its respective subsidiaries that occurs after the effective date of the Helocyte Founders Agreement and ending on the date when Fortress no longer has majority voting control in Helocyte’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one half percent (4.5%) of Helocyte’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2015Q1	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Avenue Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenue’s voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one half percent (4.5%) of Avenue’s annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, the Company will pay a one-time change in control fee equal to five (5x) times the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2016	fbio	Stock Issued For Exercise Of Warrants StockIssuedForExerciseOfWarrants	10000	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2500
CY2016	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	793000	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1682000	USD
CY2015	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2014	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2016	fbio	Elimination Of Revenue EliminationOfRevenue	1300000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	14600000	USD
CY2016Q4	us-gaap	Pledged Assets Separately Reported Loans Pledged As Collateral At Fair Value PledgedAssetsSeparatelyReportedLoansPledgedAsCollateralAtFairValue	600000	USD
CY2015Q4	us-gaap	Pledged Assets Separately Reported Loans Pledged As Collateral At Fair Value PledgedAssetsSeparatelyReportedLoansPledgedAsCollateralAtFairValue	600000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2016	fbio	Non Cash Or Part Non Cash Acquisition Warrants Issuable NonCashOrPartNonCashAcquisitionWarrantsIssuable	13406000	USD
CY2016	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	920000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	USD
CY2016Q4	fbio	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Warrants Issuable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedWarrantsIssuable	13406000	USD
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y11M5D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y10M28D
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	16500000	USD
CY2016	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	84000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1650000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1649000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1649000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1654000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1649000	USD
CY2016Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	7740000	USD
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	0.2	USD
CY2016Q3	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	2295	acre
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	53000	USD
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	15991000	USD
CY2016Q4	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	100000	shares
CY2016	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 27.5pt; MARGIN: 0in 0in 0pt; size: 8.5in 11.0in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" align="left"><b>Reclassifications</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" align="left"><b> </b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0px; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0px" align="left">Certain prior period amounts may have been reclassified to conform to the current year presentation.<b> </b></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28000000	USD
CY2016	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0.02	pure
CY2015	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0	pure
CY2014	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.02	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0	pure
CY2015Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	2485000	USD
CY2016	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	0	USD
CY2016Q3	us-gaap	Professional Fees ProfessionalFees	0.2	USD
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1779365	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	-648864	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1130501	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1105501	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.37
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.51
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.73
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.71
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	666396000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	602451000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	602451000	USD
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y3M25D
CY2016Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	0.176
CY2016Q4	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	17600	USD
CY2016Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	10000	shares
CY2015Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	10000	shares
CY2015Q3	fbio	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	2500	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.00
CY2015Q3	fbio	Stock Issued During Period Value Of Warrants Excercised StockIssuedDuringPeriodValueOfWarrantsExcercised	50000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	53000000	USD
CY2016	fbio	Lease Sharing Agreements Contributions To Property Under Lease LeaseSharingAgreementsContributionsToPropertyUnderLease	4800000	USD
CY2016Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	-509000	USD
CY2016Q4	fbio	Agreement Description Terms AgreementDescriptionTerms	(i) pay an equity fee in shares of common stock, payable within five (5) business days of the closing of any equity or debt financing for Cellvation or any of its respective subsidiaries that occurs after the effective date of the Cellvation Founders Agreement and ending on the date when the Company no longer has majority voting control in Cellvations voting equity, equal to two and one-half (2.5%) of the gross amount of any such equity or debt financing; and (ii) pay a cash fee equal to four and one-half percent (4.5%) of Cellvations annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a Change in Control, Cellvation will pay a one-time change in control fee equal to five (5x) times the product of (A) net sales for the twelve (12) months immediately preceding the change in control and (B) four and one-half percent (4.5%).

Files In Submission

Name	View Source	Status
0001144204-17-015137-index-headers.html	Edgar Link	pending
0001144204-17-015137-index.html	Edgar Link	pending
0001144204-17-015137.txt	Edgar Link	pending
0001144204-17-015137-xbrl.zip	Edgar Link	pending
fbio-20161231.xml	Edgar Link	completed
fbio-20161231.xsd	Edgar Link	pending
fbio-20161231_cal.xml	Edgar Link	unprocessable
fbio-20161231_def.xml	Edgar Link	unprocessable
fbio-20161231_lab.xml	Edgar Link	unprocessable
fbio-20161231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pg34img01_10k.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v461010_10k.htm	Edgar Link	pending
v461010_ex21-1.htm	Edgar Link	pending
v461010_ex23-1.htm	Edgar Link	pending
v461010_ex23-2.htm	Edgar Link	pending
v461010_ex31-1.htm	Edgar Link	pending
v461010_ex31-2.htm	Edgar Link	pending
v461010_ex32-1.htm	Edgar Link	pending
v461010_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2017 Q1 Form 10-K Financial Statement

#000114420417015137 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2017 Q1 Form 10-K Financial Statement

#000114420417015137 Filed on March 16, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio